CytoMed Therapeutics Business Summary

CytoMed Therapeutics Ltd (GDTC) is a clinical-stage biopharmaceutical company that generates revenue through a dual-track model comprising cell-based immunotherapy R&D and commercial cell banking services. Its primary business segments include the development of "off-the-shelf" allogeneic therapies—specifically gamma delta T (γδ T) cells and iPSC-derived natural killer (NK) cells—and the processing and banking of cord blood and adult stem cells via its LongevityBank subsidiary. The company leverages a low-cost Southeast Asian manufacturing infrastructure to position itself as a cost-efficient alternative to Western CAR-T providers. Direct competitors include Fate Therapeutics, Iovance Biotherapeutics, and Autolus Therapeutics; CytoMed distinguishes itself by focusing on the innate immune system's γδ T cells, which offer reduced graft-versus-host disease risks and enhanced solid tumor penetration compared to traditional alpha-beta T cell therapies. The leadership team is anchored by founder and Executive Chairman Chee Kong (Peter) Choo, a corporate finance veteran with over 20 years of experience who recently increased his stake to approximately 22% to signal long-term commitment. Scientific operations are led by co-founder Dr. Jieming Zeng, who serves as Chief Scientific and Medical Officer and brings over two decades of research pedigree from Singapore’s Agency for Science, Technology and Research (A*STAR). The executive suite is rounded out by CFO Yvonne Goh, formerly of SBI Offshore, and Chief Clinical Officer Dr. Lucas Luk Tien Wee, who oversees the company’s expanding Phase I clinical trials in Singapore and Malaysia. Notable board members include Professor Yuin Han Loh, a recognized expert in stem cell biology, reflecting the company's deep roots in the Singaporean biotech ecosystem.